Abstract Number: 0063 • ACR Convergence 2022
Implementability of a SLE Medication Adherence Intervention
Background/Purpose: Medication nonadherence in SLE is common and negatively impacts patient outcomes. Yet, little is known about how to improve medication adherence in patients with…Abstract Number: 0126 • ACR Convergence 2022
Should Arthrocentesis Be Attempted in the Symptomatic but Non-Effusive Knee?
Background/Purpose: Arthrocentesis of the painful but non-effusive knee is usually not undertaken due to a high arthrocentesis failure rate. We hypothesized that compression-assisted arthrocentesis of…Abstract Number: 0173 • ACR Convergence 2022
Cutaneous Manifestations, Clinical Trials, Safety Efficacy and Safety of Lenabasum in the Phase 3 DeterMine Trial in Dermatomyositis
Background/Purpose: Safe and effective treatments are of significant unmet need in DM. Lenabasum, a CB2 agonist that activates resolution of inflammation, improved skin disease, patient-reported…Abstract Number: 0201 • ACR Convergence 2022
Real-World Evidence from Social Media Provides Insights into Patient Mental Health Outcomes in the Management of Gout
Background/Purpose: The ability to actively listen to and interpret the patient experience is vital to effectively address the needs of individuals within a particular community.…Abstract Number: 0571 • ACR Convergence 2022
National Rollout of a Medication Safety Dashboard to Improve Testing for Latent Infections Among Biologic/targeted Synthetic DMARD Users Within the Veterans Health Administration: Initial Results
Background/Purpose: Guidelines recommend testing for latent hepatitis B virus (HBV), hepatitis C virus (HCV), and tuberculosis (TB) infection prior to initiating biologics or targeted synthetic…Abstract Number: 1269 • ACR Convergence 2022
Implementing RAPID-3 Using Electronic Patient Portal and Point of Care Entry
Background/Purpose: The treat-to-target approach endorsed by the ACR for rheumatoid arthritis requires frequent monitoring of disease activity using validated instruments, with changes to the treatment…Abstract Number: 1809 • ACR Convergence 2022
Impact of Colchicine Prophylaxis on Cardiovascular Outcome Among Gout Patients: A Secondary Analysis of CARES Trial
Background/Purpose: Low-dose colchicine has been demonstrated to reduce cardiovascular (CV) events in two recent large cardiovascular trials. Gout patients, for whom colchicine is a highly relevant…Abstract Number: 2003 • ACR Convergence 2022
Anti-rheumatic Treatment Modulates Expression of the Glycolytic Enzyme PFKFB3 in CD14+ Monocytes of Patients with Rheumatoid Arthritis, Which Contributes to Dissimilarities of the IFN Signature
Background/Purpose: Combination of IFN-stimulated genes known as IFN signature, helps to predict disease activity and treatment response in several autoimmune diseases, including rheumatoid arthritis (RA).…Abstract Number: 2263 • ACR Convergence 2022
Nanotherapeutic Approaches for the Treatment of Post-traumatic Osteoarthritis
Background/Purpose: Osteoarthritis (OA) represents the most common form of arthritis and is a major cause of morbidity in the aging population. Post-traumatic OA (PTOA) is…Abstract Number: L02 • ACR Convergence 2021
COVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and immunogenicity…Abstract Number: 0462 • ACR Convergence 2021
Remotely Delivered Cognitive Behavioural and Personalised Exercise Interventions Reduce Fatigue Severity and Impact in Inflammatory Rheumatic Diseases: Results from a Multi-centre Randomised Controlled Parallel Group Trial
Background/Purpose: Inflammatory rheumatic disease (IRD) related fatigue is pervasive and disabling, even in otherwise stable disease. Although cognitive-behavioural approaches (CBAs) and personalised exercise programmes (PEP)…Abstract Number: 0488 • ACR Convergence 2021
Efficacy and Safety of Brepocitinib (Tyrosine Kinase 2/Janus Kinase 1 Inhibitor) for the Treatment of Active Psoriatic Arthritis: Results from a Phase 2b Randomized Controlled Trial
Background/Purpose: Brepocitinib is a small-molecule tyrosine kinase 2/Janus kinase 1 inhibitor that has shown promising results in an oral formulation for plaque psoriasis and alopecia…Abstract Number: 0623 • ACR Convergence 2021
Intervention to Improve SLE Medication Adherence
Background/Purpose: Medication nonadherence is as high as 80% among SLE patients and leads to higher morbidity, mortality, and healthcare costs. Both the under-recognition of nonadherence…Abstract Number: 0773 • ACR Convergence 2021
Janus Kinase (JAK) Inhibition with Baricitinib: Dosing and Patient-Reported Outcomes in Refractory Juvenile Dermatomyositis
Background/Purpose: Juvenile dermatomyositis (JDM) is a systemic autoimmune disease with a prominent interferon (IFN) signature. Treatment often requires prolonged high-dose steroids and other immunosuppressive medications.…Abstract Number: 1746 • ACR Convergence 2021
Baricitinib Decreases Anti-dsDNA and IgG Antibodies in Adults with Systemic Lupus Erythematosus from a Phase 2 Double-Blind, Randomized, Placebo-Controlled Trial
Background/Purpose: Baricitinib (BARI), an oral, selective Janus kinase (JAK)1 and JAK2 inhibitor, improved disease activity in adults with systemic lupus erythematosus (SLE) receiving standard background…
- 1
- 2
- 3
- 4
- Next Page »